$BLUE
bluebird bio, Inc.

2016 Q4 Form 10-Q Financial Statement

#000156459016027024 Filed on November 02, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $1.552M $1.552M $1.324M
YoY Change 5.51% 17.22% -79.2%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.20M $14.60M $13.70M
YoY Change 12.5% 6.57% 107.58%
% of Gross Profit
Research & Development $57.10M $64.00M $30.40M
YoY Change 59.94% 110.53% 82.59%
% of Gross Profit
Depreciation & Amortization $2.520M $2.380M $1.870M
YoY Change 23.53% 27.27% 21.43%
% of Gross Profit
Operating Expenses $73.89M $79.69M $44.45M
YoY Change 46.51% 79.28% 166.99%
Operating Profit -$72.34M -$78.14M -$43.13M
YoY Change 47.74% 81.19% 153.54%
Interest Expense -$600.0K -$1.100M -$400.0K
YoY Change -146.15% 175.0% 300.0%
% of Operating Profit
Other Income/Expense, Net $900.0K $900.0K $300.0K
YoY Change 800.0% 200.0% -1600.0%
Pretax Income -$71.40M -$77.20M -$42.90M
YoY Change 50.95% 79.96% 151.91%
Income Tax -$100.0K -$200.0K $100.0K
% Of Pretax Income
Net Earnings -$71.36M -$77.03M -$42.92M
YoY Change 50.95% 79.45% 152.05%
Net Earnings / Revenue -4598.2% -4962.95% -3241.99%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.874M -$2.070M -$1.179M
COMMON SHARES
Basic Shares Outstanding 37.30M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $704.4M $601.0M $707.5M
YoY Change 36.01% -15.05% 228.46%
Cash & Equivalents $278.9M $245.2M $417.5M
Short-Term Investments $425.5M $355.8M $290.0M
Other Short-Term Assets $3.085M $7.900M $5.700M
YoY Change -48.58% 38.6% -27.85%
Inventory
Prepaid Expenses $8.209M
Receivables
Other Receivables
Total Short-Term Assets $724.2M $608.8M $713.2M
YoY Change 38.22% -14.64% 219.36%
LONG-TERM ASSETS
Property, Plant & Equipment $157.0M $131.7M $61.60M
YoY Change 89.99% 113.86% 311.27%
Goodwill $13.13M $13.13M
YoY Change 0.0%
Intangibles $20.69M $21.63M
YoY Change -15.38%
Long-Term Investments $180.5M $126.7M $194.2M
YoY Change -48.1% -34.76% 301.24%
Other Assets $22.68M $16.25M $10.20M
YoY Change 118.91% 59.28% 777.8%
Total Long-Term Assets $393.9M $309.5M $304.4M
YoY Change -17.66% 1.66% 184.82%
TOTAL ASSETS
Total Short-Term Assets $724.2M $608.8M $713.2M
Total Long-Term Assets $393.9M $309.5M $304.4M
Total Assets $1.118B $918.3M $1.018B
YoY Change 11.55% -9.76% 208.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.66M $6.710M $3.500M
YoY Change 115.72% 91.71% -3.87%
Accrued Expenses $49.50M $50.10M $19.50M
YoY Change 114.29% 156.92% 101.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $74.53M $67.59M $33.60M
YoY Change 84.63% 101.16% -12.78%
LONG-TERM LIABILITIES
Long-Term Debt $120.1M $100.0M $43.80M
YoY Change 94.02% 128.31%
Other Long-Term Liabilities $120.0K $56.20M $50.50M
YoY Change -49.37% 11.29% 15534.67%
Total Long-Term Liabilities $120.0K $156.2M $94.30M
YoY Change -49.37% 65.64% 29095.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $74.53M $67.59M $33.60M
Total Long-Term Liabilities $120.0K $156.2M $94.30M
Total Liabilities $248.7M $223.7M $128.6M
YoY Change 63.78% 73.95% 88.28%
SHAREHOLDERS EQUITY
Retained Earnings -$577.7M
YoY Change 83.87%
Common Stock $407.0K
YoY Change 10.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $869.4M $694.5M $889.0M
YoY Change
Total Liabilities & Shareholders Equity $1.118B $918.3M $1.018B
YoY Change 11.55% -9.76% 208.18%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$71.36M -$77.03M -$42.92M
YoY Change 50.95% 79.45% 152.05%
Depreciation, Depletion And Amortization $2.520M $2.380M $1.870M
YoY Change 23.53% 27.27% 21.43%
Cash From Operating Activities -$69.11M -$39.44M -$29.06M
YoY Change 108.85% 35.72% 39.91%
INVESTING ACTIVITIES
Capital Expenditures -$13.02M -$8.950M -$1.050M
YoY Change 278.49% 752.38% -40.68%
Acquisitions
YoY Change
Other Investing Activities -$119.5M $68.48M -$148.7M
YoY Change -45.1% -146.06% -14.46%
Cash From Investing Activities -$132.6M $59.54M -$149.7M
YoY Change -40.07% -139.77% -14.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 239.8M 2.430M 3.000M
YoY Change 23406.86% -19.0% -97.28%
NET CHANGE
Cash From Operating Activities -69.11M -39.44M -29.06M
Cash From Investing Activities -132.6M 59.54M -149.7M
Cash From Financing Activities 239.8M 2.430M 3.000M
Net Change In Cash 38.10M 22.53M -175.8M
YoY Change -115.04% -112.82% 104.13%
FREE CASH FLOW
Cash From Operating Activities -$69.11M -$39.44M -$29.06M
Capital Expenditures -$13.02M -$8.950M -$1.050M
Free Cash Flow -$56.09M -$30.49M -$28.01M
YoY Change 89.17% 8.85% 47.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
353680000
CY2016Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
126681000
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
131737000
CY2016Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
21634000
CY2016Q3 us-gaap Goodwill
Goodwill
13128000
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
16247000
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6710000
CY2016Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
54672000
CY2016Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6209000
CY2016Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
10995000
CY2016Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
41756000
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
67591000
CY2016Q3 us-gaap Assets
Assets
918262000
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37303678
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164269000
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Revenues
Revenues
4603000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
630000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
44451000
us-gaap Operating Expenses
OperatingExpenses
132685000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33979000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
103000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1455000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
121000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-77219000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42821000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-119387000
CY2016Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-100000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
800000
blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
2099000
blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
2015000
us-gaap Share Based Compensation
ShareBasedCompensation
30831000
us-gaap Other Noncash Expense
OtherNoncashExpense
2166000
us-gaap Other Noncash Expense
OtherNoncashExpense
528000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3857000
CY2016Q3 blue Construction Financing Obligation
ConstructionFinancingObligation
99991000
us-gaap Operating Expenses
OperatingExpenses
200098000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-78140000
CY2016Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-194000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.52
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2803000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-77203000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7132000
us-gaap Net Income Loss
NetIncomeLoss
-119508000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5381000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3515000
us-gaap Share Based Compensation
ShareBasedCompensation
31011000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8909000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
485703000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
69665000
blue Proceeds From Public Offering Of Common Stock Net Of Issuance Costs
ProceedsFromPublicOfferingOfCommonStockNetOfIssuanceCosts
477247000
blue Payments Of Contingent Purchase Price Consideration
PaymentsOfContingentPurchasePriceConsideration
453000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
417510000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-190688000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1014000
CY2016Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
68000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
964000
CY2015Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
3584000
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
605000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
495000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9529000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30831000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31011000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2717000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1210000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
623000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
24099000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5320000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
6117000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
12643000
blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
1805000
blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
-640000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-120541000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-65344000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
4379000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
8816000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15005000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3618000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
145135000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
470499000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
356684000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
132239000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
7500000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
199665000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-350694000
blue Payments Of Contingent Purchase Price Consideration
PaymentsOfContingentPurchasePriceConsideration
2025000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3786000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1761000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
80885000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
347845000
blue Construction Financing Obligation Non Cash
ConstructionFinancingObligationNonCash
38090000
blue Construction Financing Obligation Non Cash
ConstructionFinancingObligationNonCash
43777000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2479000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1475000
blue Receivable For Stock Option Exercise
ReceivableForStockOptionExercise
374000
blue Receivable For Stock Option Exercise
ReceivableForStockOptionExercise
24000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bluebird bio, Inc. (the &#8220;Company&#8221; or &#8220;bluebird&#8221;) was incorporated in Delaware on April&#160;16, 1992, and is headquartered in Cambridge, Massachusetts. The Company researches, develops, manufactures and plans to commercialize gene therapies for the treatment of severe genetic and rare diseases and in the field of T cell-based immunotherapy. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide general and administrative support for these operations.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div>
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:3.33%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Estimates are used in the following areas, among others: fair value estimates used to assess potential impairment of long-lived assets, construction financing lease obligations, contingent consideration, stock-based compensation expense, accrued expenses, revenue and income taxes. Actual results could materially differ from those estimates.</p></div>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1992-04-16
CY2016Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
482544000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
703785000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
107000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
22000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
164000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
701494000
CY2016Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
727641000
CY2016Q3 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
7180000
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
865763000
CY2015Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
8665000
us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Three months or less
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2016Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
255800000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
638100000
CY2016Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2016Q3 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2015Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2016Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
3913000
CY2016Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
142811000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
89435000
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11074000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6821000
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8920000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5935000
CY2016Q3 blue Accrued Goods And Services
AccruedGoodsAndServices
23855000
CY2015Q4 blue Accrued Goods And Services
AccruedGoodsAndServices
15876000
CY2016Q3 blue Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
15208000
CY2015Q4 blue Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
277000
CY2016Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2103000
CY2013Q2 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P9Y
CY2013Q2 blue Area Of Leased Space
AreaOfLeasedSpace
43600
CY2013Q2 blue Lease Amendment Effective Month And Year
LeaseAmendmentEffectiveMonthAndYear
2014-06
CY2013Q2 blue Additional Lease Space Agreement
AdditionalLeaseSpaceAgreement
9900
CY2013Q2 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
200000
CY2014Q4 us-gaap Operating Leases Rent Expense Contingent Rentals
OperatingLeasesRentExpenseContingentRentals
300000
CY2013Q2 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P5Y
CY2013Q2 blue Landlord Contribution For Leasehold Improvements
LandlordContributionForLeaseholdImprovements
7800000
CY2013Q2 blue Letter Of Credit Related To New Lease Agreement
LetterOfCreditRelatedToNewLeaseAgreement
1300000
CY2016Q3 blue Letter Of Credit Related To New Lease Agreement
LetterOfCreditRelatedToNewLeaseAgreement
600000
CY2013Q2 blue Lease Starting Date
LeaseStartingDate
2013-06-03
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
1500000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1200000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9905000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3532000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
944000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
273000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
11.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
336000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3867000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1850000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3776000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
48.74
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
50.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
48.88
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
51.74
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
38.04
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
51.53
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3200000
CY2016Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
200000
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4133000
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3907000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4133000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3907000

Files In Submission

Name View Source Status
0001564590-16-027024-index-headers.html Edgar Link pending
0001564590-16-027024-index.html Edgar Link pending
0001564590-16-027024.txt Edgar Link pending
0001564590-16-027024-xbrl.zip Edgar Link pending
blue-10q_20160930.htm Edgar Link pending
blue-20160930.xml Edgar Link completed
blue-20160930.xsd Edgar Link pending
blue-20160930_cal.xml Edgar Link unprocessable
blue-20160930_def.xml Edgar Link unprocessable
blue-20160930_lab.xml Edgar Link unprocessable
blue-20160930_pre.xml Edgar Link unprocessable
blue-ex1035_1084.htm Edgar Link pending
blue-ex1036_1085.htm Edgar Link pending
blue-ex311_8.htm Edgar Link pending
blue-ex312_9.htm Edgar Link pending
blue-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2016110217525330411541.jpg Edgar Link pending
g2016110217541200810168.jpg Edgar Link pending
g2016110217541203210169.jpg Edgar Link pending
g2016110217541206210170.jpg Edgar Link pending
g2016110217541208710171.jpg Edgar Link pending
g2016110217541211210172.jpg Edgar Link pending
g2016110217541223010173.jpg Edgar Link pending
g2016110217541228910173.jpg Edgar Link pending
g2016110217541360310173.jpg Edgar Link pending
g2016110217541364710174.jpg Edgar Link pending
g2016110217541366910175.jpg Edgar Link pending
g2016110217541372510175.jpg Edgar Link pending
g2016110217541374010175.jpg Edgar Link pending
g2016110217541384310176.jpg Edgar Link pending
g2016110217541393810176.jpg Edgar Link pending
g2016110217541401110177.jpg Edgar Link pending
g2016110217541406610178.jpg Edgar Link pending
g2016110217541409610179.jpg Edgar Link pending
g2016110217541414310180.jpg Edgar Link pending
g2016110217541421910181.jpg Edgar Link pending
g2016110217541426410182.jpg Edgar Link pending
g2016110217541617910183.jpg Edgar Link pending
g2016110217541620810184.jpg Edgar Link pending
g2016110217541623710185.jpg Edgar Link pending
g2016110217541766710186.jpg Edgar Link pending
g2016110217541770210187.jpg Edgar Link pending
g2016110217541773510188.jpg Edgar Link pending
g2016110217542016710189.jpg Edgar Link pending
g2016110217542020910190.jpg Edgar Link pending
g2016110217542024510191.jpg Edgar Link pending
g2016110217542029110192.jpg Edgar Link pending
g2016110217542032810193.jpg Edgar Link pending
g2016110217542284410194.jpg Edgar Link pending
g2016110217542290910195.jpg Edgar Link pending
g2016110217542300910196.jpg Edgar Link pending
g2016110217542327710197.jpg Edgar Link pending
g2016110217542348310198.jpg Edgar Link pending
g2016110217542357110199.jpg Edgar Link pending
g2016110217542361610200.jpg Edgar Link pending
g2016110217542371810201.jpg Edgar Link pending
g2016110217542384610202.jpg Edgar Link pending
g2016110217542410610203.jpg Edgar Link pending
g2016110217542657310204.jpg Edgar Link pending
g2016110217542662810205.jpg Edgar Link pending
g2016110217542667810206.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending